Best et al.[38] also reported that RNA profiles from TEP could be used to discriminate tumor patients with different status of therapy-targeting oncogenes, such as KRAS-mut vs KRAS-wt in CRC, HBC, NSCLC, and PAAD patients, EGFR-mut vs EGFR-wt in NSCLC patients, MET+ vs MET- in NSCLC patients, PIK3CA-mut vs PIK3CA-wt in BRCA, HER2+ vs HER2- in BRCA, as well as triple-negative breast cancer. This evidence concerns the gene KRAS and pancreatic adenocarcinoma.